Inflammatory bowel disease: clinical aspects and established and evolving therapies

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135

Controlled trial of metronidazole treatment for prevention of crohn's recurrence after ileal resection

Rutgeerts, P., Hiele, M., Geboes, K., Peeters, M., Penninckx, F., Aerts, R., & Kerremans, R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90121-3 · Cited by 743

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease☆

Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636

Epidermal Growth Factor Enemas with Oral Mesalamine for Mild-to-Moderate Left-Sided Ulcerative Colitis or Proctitis

Sinha, A., Nightingale, J. M. D., West, K. P., Berlanga-Acosta, J., & Playford, R. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013136 · Cited by 303

Inflammatory bowel disease

Abraham, C., & Cho, J. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804647 · Cited by 2,712

Inflammatory bowel disease: cause and immunobiology

Baumgart, D. C., & Carding, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60750-8 · Cited by 2,147

Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders

Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910

Inflammatory bowel disease

Kaser, A., Zeissig, S., & Blumberg, R. S. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101225 · Cited by 1,806

Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract

Monteleone, I., Rizzo, A., Sarra, M., Sica, G., Sileri, P., Biancone, L., MacDonald, T. T., Pallone, F., & Monteleone, G. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.007 · Cited by 656

The Probiotic Preparation, VSL#3 Induces Remission in Patients With Mild-to-Moderately Active Ulcerative Colitis

Sood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.016 · Cited by 513

Role of the microbiota in inflammatory bowel diseases

Nagalingam, N. A., & Lynch, S. V. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21866 · Cited by 315

Anti-inflammatory effect of vagus nerve stimulation in a rat model of inflammatory bowel disease

Meregnani, J., Clarençon, D., Vivier, M., Peinnequin, A., Mouret, C., Sinniger, V., Picq, C., Job, A., Canini, F., Jacquier-Sarlin, M., et al. (2011) · Autonomic Neuroscience · doi:10.1016/j.autneu.2010.10.007 · Cited by 310

The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models

Martín, R., Chain, F., Miquel, S., Lu, J., Gratadoux, J.-J., Sokol, H., Verdu, E. F., Bercik, P., Bermúdez-Humarán, L. G., & Langella, P. (2014) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000440815.76627.64 · Cited by 284

Cinnamaldehyde inhibits pro-inflammatory cytokines secretion from monocytes/macrophages through suppression of intracellular signaling

Chao, L. K., Hua, K.-F., Hsu, H.-Y., Cheng, S.-S., Lin, I.-F., Chen, C.-J., Chen, S.-T., & Chang, S.-T. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2007.07.016 · Cited by 250

Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities

Iliev, I. D., Ananthakrishnan, A. N., & Guo, C.-J. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01163-0 · Cited by 249

Psychological adjustment and autonomic disturbances in inflammatory bowel diseases and irritable bowel syndrome

Pellissier, S., Dantzer, C., Canini, F., Mathieu, N., & Bonaz, B. (2010) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.10.004 · Cited by 198

Contribution of STAT3 to inflammatory and fibrotic diseases and prospects for its targeting for treatment

Kasembeli, M. M., Bharadwaj, U., Robinson, P., & Tweardy, D. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082299 · Cited by 199

Macrophage-based nanotherapeutic strategies in ulcerative colitis

Zhang, J., Zhao, Y., Hou, T., Zeng, H., Kalambhe, D., Wang, B., Shen, X., & Huang, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.047 · Cited by 160

Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus

Hamady, Z. Z. R., Scott, N., Farrar, M. D., Lodge, J. P. A., Holland, K. T., Whitehead, T., & Carding, S. R. (2010) · Gut · doi:10.1136/gut.2008.176131 · Cited by 131

Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof‐of‐concept study

CORINALDESI, R., STANGHELLINI, V., CREMON, C., GARGANO, L., COGLIANDRO, R. F., DE GIORGIO, R., BARTESAGHI, G., CANOVI, B., & BARBARA, G. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04041.x · Cited by 131

Potential Benefits of Dietary Fibre Intervention in Inflammatory Bowel Disease

Wong, C., Harris, P., & Ferguson, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060919 · Cited by 116

The Role of Psychological Stress in Inflammatory Bowel Disease: Quality Assessment of Methods of 18 Prospective Studies and Suggestions for Future Research

Cámara, R. J. A., Ziegler, R., Begré, S., Schoepfer, A. M., & von Känel, R. (2009) · Digestion · doi:10.1159/000226087 · Cited by 106

Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases

Prosperi, D., Colombo, M., Zanoni, I., & Granucci, F. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.010 · Cited by 106

Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: Results of the ISSEO survey

Nahon, S., Lahmek, P., Saas, C., Durance, C., Olympie, A., Lesgourgues, B., & Gendre, J.-P. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21482 · Cited by 102

Predictors of health-related quality of life and adherence in Crohn's disease and ulcerative colitis: implications for clinical management

Tabibian, A., Tabibian, J. H., Beckman, L. J., Raffals, L. L., Papadakis, K. A., & Kane, S. V. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3471-1 · Cited by 89

Sex Differences in the Gut-Brain Axis: Implications for Mental Health

Holingue, C., Budavari, A. C., Rodriguez, K. M., Zisman, C. R., Windheim, G., & Fallin, M. D. (2020) · Current Psychiatry Reports · doi:10.1007/s11920-020-01202-y · Cited by 85

Gut Organoid as a New Platform to Study Alginate and Chitosan Mediated PLGA Nanoparticles for Drug Delivery

Davoudi, Z., Peroutka-Bigus, N., Bellaire, B., Jergens, A., Wannemuehler, M., & Wang, Q. (2021) · Marine Drugs · doi:10.3390/md19050282 · Cited by 84

Prophylactic systemic P2X7 receptor blockade prevents experimental colitis

Marques, C. C., Castelo-Branco, M. T., Pacheco, R. G., Buongusto, F., do Rosário, A., Schanaider, A., Coutinho-Silva, R., & de Souza, H. S. P. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.10.012 · Cited by 78

Inflammatory Bowel disease [IBD] and physical activity: A study on the impact of diagnosis on the level of exercise amongst patients with IBD

Gatt, K., Schembri, J., Katsanos, K. H., Christodoulou, D., Karmiris, K., Kopylov, U., Pontas, C., Koutroubakis, I. E., Foteinogiannopoulou, K., Fabian, A., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjy214 · Cited by 76

Remodeling of the Candida glabrata cell wall in the gastrointestinal tract affects the gut microbiota and the immune response

Charlet, R., Pruvost, Y., Tumba, G., Istel, F., Poulain, D., Kuchler, K., Sendid, B., & Jawhara, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-21422-w · Cited by 74

Mood and nonmood components of perceived stress and exacerbation of Crohnʼs disease

Cámara, R. J. A., Schoepfer, A. M., Pittet, V., Begré, S., & von Känel, R. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21623 · Cited by 67

Prevalence of depression and anxiety in people with inflammatory bowel disease and associated healthcare use: Population-based cohort study

Irving, P., Barrett, K., Nijher, M., & de Lusignan, S. (2021) · Evidence-Based Mental Health · doi:10.1136/ebmental-2020-300223 · Cited by 63

Unfractionated heparin and new heparin analogues from ascidians (chordate-tunicate) ameliorate colitis in rats

Belmiro, C. L. R., Castelo-Branco, M. T. L., Melim, L. M. C., Schanaider, A., Elia, C., Madi, K., Pavão, M. S. G., & de Souza, H. S. P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807211200 · Cited by 57

Serum biomarkers confirming stable remission in inflammatory bowel disease

Kessel, C., Lavric, M., Weinhage, T., Brueckner, M., de Roock, S., Däbritz, J., Weber, J., Vastert, S. J., & Foell, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-86251-w · Cited by 54

Safety of anti-TNF treatment in liver transplant recipients: a systematic review and meta-analysis

Westerouen van Meeteren, M. J., Hayee, B., Inderson, A., van der Meulen, A. E., Altwegg, R., van Hoek, B., Pageaux, G. P., Stijnen, T., Stein, D., & Maljaars, P. W. J. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx057 · Cited by 39

Perspectives on an Acceptance and Commitment Therapy (ACT) based program for patients with inflammatory bowel disease and comorbid anxiety and/or depressive symptoms.

Dober, M., Mikocka-Walus, A., Evans, S., Beswick, L., Emerson, C., & Olive, L. (2021) · Psychotherapy Research · doi:10.1080/10503307.2020.1813915 · Cited by 25

DrugGenEx-net: A novel computational platform for systems pharmacology and gene expression-based drug repurposing

Issa, N. T., Kruger, J., Wathieu, H., Raja, R., Byers, S. W., & Dakshanamurthy, S. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1065-y · Cited by 22

Ulcerative colitis as a novel cause of increased need for levothyroxine

Virili, C., Stramazzo, I., Santaguida, M. G., Bruno, G., Brusca, N., Capriello, S., Cellini, M., Severi, C., Gargano, L., & Centanni, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00233 · Cited by 20

Use of helminth therapy for management of ulcerative colitis and Crohn's disease: a systematic review

Shields, V. E., & Cooper, J. (2022) · Parasitology · doi:10.1017/s0031182021001670 · Cited by 18

Genetically Engineered Bacteria as a Promising Therapeutic Strategy Against Cancer: A Comprehensive Review

Zahedifard, Z., Mahmoodi, S., & Ghasemian, A. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2738 · Cited by 12

The influence of family pattern abnormalities in the early stages of life on the course of inflammatory bowel diseases

Włodarczyk, M., Sobolewska-Włodarczyk, A., Stec-Michalska, K., Fichna, J., & Wiśniewska-Jarosińska, M. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.04.008 · Cited by 11